Latest News Releases
 
*DISCLAIMER*: Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, Frankly and this Station make no warranties or representations in connection therewith.
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced findings from two new analyses of the landmark EMPA-REG OUTCOME® trial, presented at the 78th American Diabetes Association (ADA) Scientific...

New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes
New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

Amgen (NASDAQ:AMGN) today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type...

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer

Array BioPharma Inc. (NASDAQ: ARRY) today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF...

Cellenkos, Inc. Announces Neuroinflammation Research Collaboration with The University of Texas Health Science Center at Houston
Cellenkos, Inc. Announces Neuroinflammation Research Collaboration with The University of Texas Health Science Center at Houston

Cellenkos™ and The University Of Texas Health Science Center at Houston today announce a research collaboration for application of cord blood-derived regulatory T cells (CK0801) as adoptive therapy for treatment of...

ALK and ROS1 Clones from CST Featured in Latest Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer
ALK and ROS1 Clones from CST Featured in Latest Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer

Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services announced that two of its antibody clones, ALK (D5F3®) and ROS1 (D4D6®), were featured in an article authored by the Tumor Biomarker...

Digital Technology Consortium Report Provides Window into Future Trends for Digital Marketing Budget, Staffing and Performance Measurement
Digital Technology Consortium Report Provides Window into Future Trends for Digital Marketing Budget, Staffing and Performance Measurement

Pharmaceutical companies are increasingly using digital engagement channels to more effectively communicate with their customers.

Trovagene Announces Leadership Change
Trovagene Announces Leadership Change

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced that William Welch has resigned...

Global Genome Engineering Market, 2018-2024 - Market to Grow with a CAGR of 11.80%
Global Genome Engineering Market, 2018-2024 - Market to Grow with a CAGR of 11.80%

The "Genome Engineering Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering. The report predicts the global genome engineering...

Eidos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Eidos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced the...

Orig3n Founders Named Finalists for Ernest and Young Entrepreneur Of The Year® 2018 Award
Orig3n Founders Named Finalists for Ernest and Young Entrepreneur Of The Year® 2018 Award

Orig3n, a Boston-based biotech company pioneering the future of health through genetics and regenerative medicine, today announced that its co-founders, Robin Y. Smith, CEO, and Kate Blanchard, COO, are finalists for the...

Mezzion Pharma and NHLBI-Funded Pediatric Heart Network Complete Enrollment in a Pivotal Phase 3 Clinical Trial of Udenafil in Adolescents with Fontan Surgical Palliation - an Orphan Drug Indication
Mezzion Pharma and NHLBI-Funded Pediatric Heart Network Complete Enrollment in a Pivotal Phase 3 Clinical Trial of Udenafil in Adolescents with Fontan Surgical Palliation - an Orphan Drug Indication

Mezzion Pharma and the National Heart, Lung, and Blood Institute (NHLBI) today announced that it has completed enrollment of their FUEL trial, a pivotal Phase 3 efficacy and safety trial of udenafil for the treatment of...

Nanotera Group Launches Powerful Plant Based Surfactants for the Oil Industry
Nanotera Group Launches Powerful Plant Based Surfactants for the Oil Industry

Nanotera Group has introduced higher quality, plant-based solutions to replace chemical and hazardous products in the oil & gas industry. Dedicated to protecting the environment, Nanotera now supplies powerful cleaning...

Prometic conference call to present progress report on AGM corporate action plan
Prometic conference call to present progress report on AGM corporate action plan

LAVAL, QC, June 22, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will hold a conference call on Wednesday June 27, 2018 to report on its progress in...

/C O R R E C T I O N -- CSL Behring/
/C O R R E C T I O N -- CSL Behring/

An exciting cross-section of coagulation research is being presented today by the recipients of CSL Behring's 2018 Prof. Heimburger Award at the Heimburger Symposium in Marburg, Germany.  Their work may one day have a...

Biotech's Making Great Progress
Biotech's Making Great Progress

FN Media Group Presents Microcapspeculators.com News Commentary  This is set to be the fifth consecutive quarter in which at least ten biotech companies have made it to market on U.S. exchanges and have raised at least a...

APAC Biotech and Diakonos Sign Technology Transfer and Licensing Agreement to Bring New Immunotherapy Technology to India
APAC Biotech and Diakonos Sign Technology Transfer and Licensing Agreement to Bring New Immunotherapy Technology to India

India-Based APAC Biotech and US-Based Diakonos Research sign a first-of-its-kind technology transfer and licensing agreement to bring new immunotherapy technology to India as an advancement of immuno-oncology therapeutics...

Lilly Completes Acquisition of ARMO BioSciences
Lilly Completes Acquisition of ARMO BioSciences

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO).

Dr. Kang Zhang, Chairman of Laboratory for Advanced Medicine Scientific Advisory Board, to Present at 2018 Liquid Biopsy Summit
Dr. Kang Zhang, Chairman of Laboratory for Advanced Medicine Scientific Advisory Board, to Present at 2018 Liquid Biopsy Summit

Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, announced today that Dr. Kang Zhang, Founding...

Prometic Presents New Data on NASH Drug Candidate PBI-4547
Prometic Presents New Data on NASH Drug Candidate PBI-4547

New data suggest PBI-4547 offers potential as novel therapy for liver fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes and obesity  New data to be presented at the 2018...

Replimune Appoints Dieter K. Weinand to Board of Directors
Replimune Appoints Dieter K. Weinand to Board of Directors

Replimune Group Inc., a biotechnology company developing next generation oncolytic immunotherapies, announced today it has appointed Dieter K. Weinand to its Board as an independent non-executive Director.      (Logo:...

A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant
A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant

An exciting cross-section of coagulation research is being presented today by the recipients of CSL Behring's 2018 Prof. Heimburger Award at the Heimburger Symposium in Marburg, Germany.  Their work may one day have a...

Fotona's Annual IFW Meeting attracts over 700 Laser Experts from 56 Countries
Fotona's Annual IFW Meeting attracts over 700 Laser Experts from 56 Countries

The 15th annual International Fotona Weekend, organized together with the 8th Laser and Health Academy Symposium, took place at the end of May in Portoroz, Slovenia. There was a record 100+ presentations and 700+...

Natera To Host Investor Conference Call to Discuss Strategic Roadmap in Organ Transplantation and Oncology
Natera To Host Investor Conference Call to Discuss Strategic Roadmap in Organ Transplantation and Oncology

Natera, Inc. (NASDAQ: NTRA), a leader in genetic testing and cell-free DNA analysis, will share data and roadmap for its emerging businesses in renal transplantation and oncology, during an investor call on June 27, 2018.

Natera Develops Powerful Kidney Transplant Rejection Biomarker
Natera Develops Powerful Kidney Transplant Rejection Biomarker

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA analysis, announces a powerful new kidney transplant rejection biomarker and study results in collaboration with the University of California, San Francisco, a...

Global Nanobiotechnology Industry
Global Nanobiotechnology Industry

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million. Read the full report: https://www.reportlinker.com/p04707106 The report provides separate comprehensive analytics for the US, Japan,...

Organogenesis Inc. Announces Support of American Diabetes Association
Organogenesis Inc. Announces Support of American Diabetes Association

Organogenesis Inc. – a leading regenerative medicine company committed to empowering healing – today announced it is a proud supporter of the American Diabetes Association (ADA). Organogenesis will support the production...

GenomeDx Announces Cigna Coverage for Decipher Prostate Cancer Tests
GenomeDx Announces Cigna Coverage for Decipher Prostate Cancer Tests

GenomeDx Biosciences, a leader in the field of urologic cancer genomics, announced today that Cigna® issued positive medical policy coverage for Decipher® Prostate RP and Decipher Prostate Biopsy, effective immediately....

Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center
Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

Johnson & Johnson Innovation LLC today announced the opening of JLABS @ NYC. The 30,000-square foot facility, located at the New York Genome Center in the heart of SoHo, is a collaboration between Johnson & Johnson...

GNTbm announces licensing of exclusive sales/marketing rights of anticancer drug Chidamide to Taiwan Specialty Pharma Corp. (TSPC)
GNTbm announces licensing of exclusive sales/marketing rights of anticancer drug Chidamide to Taiwan Specialty Pharma Corp. (TSPC)

GNT Biotech & Medicals Co., Ltd. (GNTbm, TPEx Emerging: 7427) announced that it has awarded exclusive sales and marketing rights in Taiwan of anticancer drug Chidamide to pharmaceutical distribution company Taiwan...

CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology
CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted data on NantCell Inc's aldoxorubicin which was published in the peer-reviewed journal...